LY-3009120

N/A

Report date: 2024/07/01 18:06:31
NME

Base Information

Drug NameLY-3009120
Drug Alias NameDP-4978LY-3009120LSN-3074753
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase A-Raf inhibitorsSerine/threonine-protein kinase B-raf inhibitorsC-Raf kinase inhibitors
TargetsSerine/threonine-protein kinase A-RafSerine/threonine-protein kinase B-rafC-Raf kinase
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaFrance +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDeciphera
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A